JP6878004B2 - リンパ形質細胞性リンパ腫を処置する方法 - Google Patents
リンパ形質細胞性リンパ腫を処置する方法 Download PDFInfo
- Publication number
- JP6878004B2 JP6878004B2 JP2016539167A JP2016539167A JP6878004B2 JP 6878004 B2 JP6878004 B2 JP 6878004B2 JP 2016539167 A JP2016539167 A JP 2016539167A JP 2016539167 A JP2016539167 A JP 2016539167A JP 6878004 B2 JP6878004 B2 JP 6878004B2
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- substituted
- group
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC=CCCC1=CC(C*)=C*C1 Chemical compound CC=CCCC1=CC(C*)=C*C1 0.000 description 31
- BDRXIHMSZOYUAN-UHFFFAOYSA-N CC(C)C(N1CCN(C)CC1)=O Chemical compound CC(C)C(N1CCN(C)CC1)=O BDRXIHMSZOYUAN-UHFFFAOYSA-N 0.000 description 1
- TXDOUCCKKNGHST-UHFFFAOYSA-N CC(C)CNC(OC(C)(C)C)=O Chemical compound CC(C)CNC(OC(C)(C)C)=O TXDOUCCKKNGHST-UHFFFAOYSA-N 0.000 description 1
- CMKSIMIQKMUUFQ-UHFFFAOYSA-N CC(C)NC(CCN(CC1)CCN1C(C)=O)=O Chemical compound CC(C)NC(CCN(CC1)CCN1C(C)=O)=O CMKSIMIQKMUUFQ-UHFFFAOYSA-N 0.000 description 1
- TVPDUFYZGFIQEP-UHFFFAOYSA-N CC(C)NC1OC1 Chemical compound CC(C)NC1OC1 TVPDUFYZGFIQEP-UHFFFAOYSA-N 0.000 description 1
- HXTKDDGTKRUJOQ-UHFFFAOYSA-N CC(C)[n]1cnc(C)c1 Chemical compound CC(C)[n]1cnc(C)c1 HXTKDDGTKRUJOQ-UHFFFAOYSA-N 0.000 description 1
- KWZYIVBVTSOZDI-LSDHQDQOSA-N CC/C(/c1cc(C(Nc2cc(C(NC3C=C(C(F)(F)F)C(CN4CCN(CC)CC4)=CC3)=O)ccc2C)=O)cnc1)=C\ON Chemical compound CC/C(/c1cc(C(Nc2cc(C(NC3C=C(C(F)(F)F)C(CN4CCN(CC)CC4)=CC3)=O)ccc2C)=O)cnc1)=C\ON KWZYIVBVTSOZDI-LSDHQDQOSA-N 0.000 description 1
- TXIOGJHPPVXTOY-UHFFFAOYSA-N CCN1CCN(C)CC1 Chemical compound CCN1CCN(C)CC1 TXIOGJHPPVXTOY-UHFFFAOYSA-N 0.000 description 1
- NCLNFEVRVZLVSW-UHFFFAOYSA-N CCN1CCN(CN(C)C)CC1 Chemical compound CCN1CCN(CN(C)C)CC1 NCLNFEVRVZLVSW-UHFFFAOYSA-N 0.000 description 1
- ACWXIBRIGIGXQJ-UHFFFAOYSA-N CCN1CCN(Cc(c(C(F)(F)F)c2)ccc2C(N[IH]I)=O)CC1 Chemical compound CCN1CCN(Cc(c(C(F)(F)F)c2)ccc2C(N[IH]I)=O)CC1 ACWXIBRIGIGXQJ-UHFFFAOYSA-N 0.000 description 1
- WYEWKJYUIYAODG-UHFFFAOYSA-N CCOC1CCOCC1 Chemical compound CCOC1CCOCC1 WYEWKJYUIYAODG-UHFFFAOYSA-N 0.000 description 1
- NQPTWMKTGPWPMX-UHFFFAOYSA-N CNC1CNC1 Chemical compound CNC1CNC1 NQPTWMKTGPWPMX-UHFFFAOYSA-N 0.000 description 1
- MMKGWMQCWJARLI-UHFFFAOYSA-N CNNC1OC1 Chemical compound CNNC1OC1 MMKGWMQCWJARLI-UHFFFAOYSA-N 0.000 description 1
- NZMMDVSZHKTASL-UHFFFAOYSA-N CSCNC1C=CC=NC1 Chemical compound CSCNC1C=CC=NC1 NZMMDVSZHKTASL-UHFFFAOYSA-N 0.000 description 1
- RIKMMFOAQPJVMX-UHFFFAOYSA-N Cc1c[nH]nc1 Chemical compound Cc1c[nH]nc1 RIKMMFOAQPJVMX-UHFFFAOYSA-N 0.000 description 1
- XKVUYEYANWFIJX-UHFFFAOYSA-N Cc1ccn[nH]1 Chemical compound Cc1ccn[nH]1 XKVUYEYANWFIJX-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N c1n[nH]c2c1cccc2 Chemical compound c1n[nH]c2c1cccc2 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361915684P | 2013-12-13 | 2013-12-13 | |
| US61/915,684 | 2013-12-13 | ||
| US201462036917P | 2014-08-13 | 2014-08-13 | |
| US62/036,917 | 2014-08-13 | ||
| PCT/US2014/070167 WO2015089481A2 (en) | 2013-12-13 | 2014-12-12 | Methods to treat lymphoplasmacytic lymphoma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017504595A JP2017504595A (ja) | 2017-02-09 |
| JP2017504595A5 JP2017504595A5 (enExample) | 2018-07-26 |
| JP6878004B2 true JP6878004B2 (ja) | 2021-05-26 |
Family
ID=53371973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016539167A Active JP6878004B2 (ja) | 2013-12-13 | 2014-12-12 | リンパ形質細胞性リンパ腫を処置する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9908872B2 (enExample) |
| EP (1) | EP3079682A4 (enExample) |
| JP (1) | JP6878004B2 (enExample) |
| AU (1) | AU2014361800B2 (enExample) |
| CA (1) | CA2932353A1 (enExample) |
| WO (1) | WO2015089481A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6879740B2 (ja) | 2013-12-13 | 2021-06-02 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | リンパ形質細胞性リンパ腫を処置する方法 |
| US9908872B2 (en) | 2013-12-13 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| JP6788583B2 (ja) | 2014-10-22 | 2020-11-25 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 増殖性疾患を処置するためのチアゾリル含有化合物 |
| SG11201805514VA (en) | 2016-01-13 | 2018-07-30 | Stora Enso Oyj | Processes for the preparation of 2,5-furandicarboxylic acid and intermediates and derivatives thereof |
| DK3423451T3 (da) | 2016-03-01 | 2022-11-28 | Propellon Therapeutics Inc | Inhibitorer af wdr5-protein-proteinbinding |
| WO2017147701A1 (en) | 2016-03-01 | 2017-09-08 | Ontario Institute For Cancer Research (Oicr) | Inhibitors of wdr5 protein-protein binding |
| WO2018098367A1 (en) * | 2016-11-22 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof |
| WO2018102366A1 (en) * | 2016-11-30 | 2018-06-07 | Ariad Pharmaceuticals, Inc. | Anilinopyrimidines as haematopoietic progenitor kinase 1 (hpk1) inhibitors |
| JP7167069B2 (ja) * | 2017-06-29 | 2022-11-08 | ライジェル ファーマシューティカルズ， インコーポレイテッド | キナーゼ阻害剤ならびに作製および使用のための方法 |
| EP3752504A4 (en) | 2018-02-14 | 2021-06-09 | Dana Farber Cancer Institute, Inc. | IRAQ DEGRADER AND USES THEREOF |
| CN108707147A (zh) * | 2018-06-20 | 2018-10-26 | 桑文军 | 一种新型微管蛋白抑制剂及其在抗肿瘤药物中的应用 |
| JP7286755B2 (ja) | 2018-07-31 | 2023-06-05 | ロクソ オンコロジー， インコーポレイテッド | （ｓ）－５－アミノ－３－（４－（（５－フルオロ－２－メトキシベンズアミド）メチル）フェニル）－１－（１，１，１－トリフルオロプロパン－２－イル）－１ｈ－ピラゾール－４－カルボキサミドの噴霧乾燥分散体および製剤 |
| KR102658602B1 (ko) | 2018-10-31 | 2024-04-19 | 길리애드 사이언시즈, 인코포레이티드 | Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물 |
| FI3873903T3 (fi) | 2018-10-31 | 2024-03-26 | Gilead Sciences Inc | Substituoituja 6-azabentsiimidatsoliyhdisteitä HPK1-inhibiittoreina |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| TW202346291A (zh) | 2022-03-23 | 2023-12-01 | 美商雷傑製藥公司 | 作為ｉｒａｋ抑制劑的嘧啶—２—基—吡唑化合物 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9816837D0 (en) * | 1998-08-04 | 1998-09-30 | Zeneca Ltd | Amide derivatives |
| CA2328962A1 (en) | 1998-04-17 | 1999-10-28 | Parker Hughes Institute | Btk inhibitors and methods for their identification and use |
| ID27652A (id) * | 1998-08-04 | 2001-04-19 | Astrazeneca Ab | Turunan amida yang digunakan sebagai inhibitor produksi sitokina |
| EP1115707B1 (en) * | 1998-09-25 | 2003-11-12 | AstraZeneca AB | Benzamide derivatives and ther use as cytokine inhibitors |
| US6306897B1 (en) | 1999-03-19 | 2001-10-23 | Parker Hughes Institute | Calanolides for inhibiting BTK |
| ES2367422T3 (es) | 2001-10-09 | 2011-11-03 | Amgen Inc. | Derivados de imidazol como agentes antiinflamatorios. |
| EP1546117A2 (en) | 2002-08-14 | 2005-06-29 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
| ES2571779T3 (es) | 2002-12-13 | 2016-05-26 | Ym Biosciences Australia Pty | Inhibidores de cinasa a base de nicotinamida |
| TW200616974A (en) * | 2004-07-01 | 2006-06-01 | Astrazeneca Ab | Chemical compounds |
| CA2589773A1 (en) * | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Pyridine carboxamide derivatives for use as anticancer agents |
| TW200635899A (en) * | 2004-12-22 | 2006-10-16 | Astrazeneca Ab | Chemical compounds |
| CN101106990B (zh) | 2005-01-26 | 2010-12-08 | Irm责任有限公司 | 用作蛋白激酶抑制剂的化合物和组合物 |
| EP1912639A4 (en) | 2005-08-08 | 2011-10-12 | Janssen Pharmaceutica Nv | Thiazolopyrimidine KINASE INHIBITORS |
| US7754717B2 (en) * | 2005-08-15 | 2010-07-13 | Amgen Inc. | Bis-aryl amide compounds and methods of use |
| DK1957461T3 (en) * | 2005-11-14 | 2016-12-19 | Genentech Inc | Bisamidhæmmere the hedgehog-signalling |
| WO2007076474A1 (en) | 2005-12-23 | 2007-07-05 | Kalypsys, Inc. | Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases |
| US20090312396A1 (en) | 2006-07-10 | 2009-12-17 | Astrazeneca Ab | Methods for cancer treatment using tak1 inhibitors |
| EA018573B1 (ru) * | 2006-09-22 | 2013-09-30 | Фармасайкликс, Инк. | Ингибиторы тирозинкиназы брутона |
| WO2008144253A1 (en) * | 2007-05-14 | 2008-11-27 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| TW200906825A (en) | 2007-05-30 | 2009-02-16 | Scripps Research Inst | Inhibitors of protein kinases |
| ES2401557T3 (es) | 2007-08-02 | 2013-04-22 | Amgen, Inc | Moduladores de Pl3 cinasas y métodos de uso |
| US8067423B2 (en) | 2007-10-23 | 2011-11-29 | Teva Pharmaceutical Industries Ltd. | Polymorphs of dasatinib isopropyl alcohol and process for preparation thereof |
| ES2396366T3 (es) | 2007-12-10 | 2013-02-21 | Concert Pharmaceuticals Inc. | Inhibidores heterocíclicos de quinasas |
| US8426424B2 (en) | 2008-05-06 | 2013-04-23 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
| PT3081552T (pt) * | 2008-08-13 | 2021-04-20 | Mitsui Chemicals Agro Inc | Agente de controlo de pragas contendo um derivado de amida e utilização do agente de controlo de pragas |
| AU2009289378A1 (en) | 2008-09-02 | 2010-03-11 | Boehringer Ingelheim International Gmbh | Novel benzamides, production thereof, and use thereof as medicaments |
| US8598174B2 (en) | 2008-11-12 | 2013-12-03 | Genetech, Inc. | Pyridazinones, method of making, and method of use thereof |
| MX2012002591A (es) | 2009-09-03 | 2012-04-02 | Allergan Inc | Compuestos como moduladores de tirosina cinasas. |
| EP2485589A4 (en) | 2009-09-04 | 2013-02-06 | Biogen Idec Inc | HETEROARYL-BTK INHIBITORS |
| US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
| KR101995013B1 (ko) | 2010-07-13 | 2019-07-02 | 에프. 호프만-라 로슈 아게 | Irak4 조절제로서 피라졸로[1,5a]피리미딘 및 티에노[3,2b]피리미딘 유도체 |
| CN103298794A (zh) | 2010-11-09 | 2013-09-11 | 塞尔卓姆有限公司 | 作为tyk2抑制剂的吡啶化合物及其氮杂类似物 |
| US20140080810A1 (en) | 2010-11-15 | 2014-03-20 | Exelixis, Inc. | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture |
| BR112013029640A2 (pt) * | 2011-05-23 | 2017-06-13 | Merck Patent Gmbh | derivados de piridina e pirazina |
| LT2718270T (lt) | 2011-06-10 | 2022-08-10 | Merck Patent Gmbh | Pirimidino ir piridino junginių, turinčių btk inhibitorinį aktyvumą, kompozicijos ir gamybos būdai |
| EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| WO2013050261A1 (en) * | 2011-10-03 | 2013-04-11 | Syngenta Participations Ag | Insecticidal 2-methoxybenzamide derivatives |
| CN104024257A (zh) | 2011-10-04 | 2014-09-03 | 吉利德卡利斯托加有限责任公司 | Pi3k的新的喹喔啉抑制剂 |
| BR112014010439A2 (pt) | 2011-11-03 | 2017-04-18 | F Hoffmann - La Roche Ag | compostos, composição farmacêutica, processo de produção, método de tratamento de uma doença ou distúrbio, métodos, kit e uso de uma composição farmacêutica |
| CA2856291C (en) | 2011-11-17 | 2020-08-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
| CA2857302C (en) | 2011-12-15 | 2020-08-25 | Novartis Ag | Use of inhibitors of the activity or function of pi3k |
| CN103405429A (zh) * | 2013-08-22 | 2013-11-27 | 中国药科大学 | 一类vegfr-2抑制剂及其用途 |
| WO2015069287A1 (en) | 2013-11-08 | 2015-05-14 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| US9908872B2 (en) | 2013-12-13 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| JP6879740B2 (ja) | 2013-12-13 | 2021-06-02 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | リンパ形質細胞性リンパ腫を処置する方法 |
| JP6788583B2 (ja) | 2014-10-22 | 2020-11-25 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 増殖性疾患を処置するためのチアゾリル含有化合物 |
-
2014
- 2014-12-12 US US15/104,005 patent/US9908872B2/en active Active
- 2014-12-12 CA CA2932353A patent/CA2932353A1/en active Pending
- 2014-12-12 EP EP14869351.8A patent/EP3079682A4/en active Pending
- 2014-12-12 WO PCT/US2014/070167 patent/WO2015089481A2/en not_active Ceased
- 2014-12-12 JP JP2016539167A patent/JP6878004B2/ja active Active
- 2014-12-12 AU AU2014361800A patent/AU2014361800B2/en not_active Ceased
-
2018
- 2018-02-23 US US15/904,143 patent/US10597387B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015089481A2 (en) | 2015-06-18 |
| EP3079682A2 (en) | 2016-10-19 |
| US20160311807A1 (en) | 2016-10-27 |
| US10597387B2 (en) | 2020-03-24 |
| AU2014361800B2 (en) | 2020-05-07 |
| US9908872B2 (en) | 2018-03-06 |
| CA2932353A1 (en) | 2015-06-18 |
| JP2017504595A (ja) | 2017-02-09 |
| WO2015089481A3 (en) | 2015-10-29 |
| EP3079682A4 (en) | 2017-08-30 |
| AU2014361800A1 (en) | 2016-06-09 |
| US20180186780A1 (en) | 2018-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6879740B2 (ja) | リンパ形質細胞性リンパ腫を処置する方法 | |
| JP6878004B2 (ja) | リンパ形質細胞性リンパ腫を処置する方法 | |
| JP6491202B2 (ja) | サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤 | |
| AU2017363307B2 (en) | Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof | |
| US10265321B2 (en) | Uses of salt-inducible kinase (SIK) inhibitors | |
| WO2022174184A1 (en) | Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer | |
| AU2014292888A1 (en) | Inhibitors of transcription factors and uses thereof | |
| KR20160003647A (ko) | Carm1 억제제 및 이의 용도 | |
| JP6788583B2 (ja) | 増殖性疾患を処置するためのチアゾリル含有化合物 | |
| WO2014063054A1 (en) | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof | |
| EP3448390A1 (en) | Hck as a therapeutic target in myd88 mutated diseases | |
| US11986471B2 (en) | Compounds and methods of use | |
| KR20250109229A (ko) | Ripk2 억제제 및 이의 용도 | |
| JP2024529487A (ja) | Ｒｏｃｋ２阻害剤およびその使用 | |
| WO2023049438A1 (en) | Grk2 inhibitors and uses thereof | |
| WO2024259328A1 (en) | Inhibitors of ripk2 and uses thereof | |
| CA3218510A1 (en) | Small molecule modulators of glucocerebrosidase activity and uses thereof | |
| WO2025250667A1 (en) | N-(1-(tert-butyl)-1 h-pyrazol-4-yl)-2-(4-((6-(quinolin-4-yl)oxy)-phenyl)acet amide derivatives as ripk2 inhibitors for the treatment of inflammatory diseases | |
| WO2025151449A1 (en) | Bifunctional p53-binding compounds and uses thereof | |
| WO2017151625A1 (en) | 4,9-dioxo-4,9-dihydronaphtho(2,3-b)furan-3-carboxmide derivatives and uses thereof for treating proliferative diseases and infectious diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171212 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171212 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180615 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180920 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181030 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190130 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190624 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190924 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191224 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200525 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200824 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200914 |
|
| RD13 | Notification of appointment of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7433 Effective date: 20201217 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20201217 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210114 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20210114 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210114 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20210303 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20210304 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210331 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210428 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6878004 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |